Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vertex Pharmaceuticals filings document the biotechnology company’s operating results, governance and product-development disclosures. Recent Form 8-K reports include quarterly and annual results releases, selected regulatory and pipeline events involving therapies such as povetacicept, and officer or director transition disclosures.
The company’s proxy materials cover board composition, director nominees, shareholder meeting matters, executive compensation and equity-award information. Vertex filings also provide formal records for disclosure topics tied to its approved medicines, clinical pipeline and governance structure as a Nasdaq-listed operating company.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported the vesting of performance-based stock awards. On January 22, 2026, he acquired 3,934 shares of Vertex common stock tied to a performance stock unit grant from February 1, 2023, and 3,883 shares tied to a performance stock unit grant from February 12, 2025, both at a price of $0 per share as earned performance shares.
The compensation committee certified achievement of the performance goals on January 22, 2026. The shares from the 2023 grant are scheduled to vest on February 13, 2026, while the 2025 grant will vest in installments beginning on February 24, 2026. Following these transactions, Atkinson directly holds 24,669 shares of Vertex common stock.
Vertex Pharmaceuticals executive Kristen Ambrose, SVP & Chief Accounting Officer, reported the acquisition of company stock tied to performance awards. On 01/22/2026, Ambrose acquired 2,950 shares of Vertex common stock at $0 per share from an earned performance stock unit award originally granted on 02/01/2023, increasing direct holdings to 10,795 shares.
On the same date, Ambrose also acquired 1,300 additional shares at $0 per share from a separate performance stock unit award granted on 02/12/2025, bringing direct ownership to 12,095 shares. The filing explains that these are earned performance shares following the compensation committee’s certification of performance-goal attainment on 01/22/2026, with the related shares scheduled to vest on 02/13/2026 and in installments beginning on 02/24/2026.
Vertex Pharmaceuticals executive David Altshuler reported stock awards tied to performance goals. On 01/22/2026, he acquired 7,866 shares of Vertex common stock and another 3,328 shares, each at a price of $0 per share, reflecting earned performance shares from prior performance stock unit awards. These awards were originally granted on 02/01/2023 and 02/12/2025 and included performance-vesting requirements that the company’s management development and compensation committee certified as achieved on 01/22/2026. After these transactions, Altshuler directly owned 34,477 shares of Vertex common stock. The 7,866-share portion is scheduled to vest on 02/13/2026, and the 3,328-share portion will vest in installments beginning on 02/24/2026.
Vertex Pharmaceuticals director Suketu Upadhyay reported an acquisition of derivative equity on Form 4. On 01/15/2026, he acquired 80.316 deferred stock units at a price of $443.56 per unit, bringing his total holdings of these derivative securities to 2,718.648 units held directly.
Each deferred stock unit represents one share of Vertex common stock and will be paid out in common stock upon the earliest of Mr. Upadhyay’s termination from the board, a change of control of the company, or his disability or death. This filing reflects a change in his deferred equity position rather than an immediate cash transaction in Vertex common shares.
Vertex Pharmaceuticals director Bruce I. Sachs reported an automatic grant of deferred stock units tied to his board service. On January 15, 2026, he acquired 107.088 deferred stock units at a reference price of $443.56 per unit, bringing his total to 15,564.521 deferred stock units held directly.
Each deferred stock unit represents one share of Vertex common stock and will be paid out in common stock at the earliest of Sachs leaving the board, a change of control of the company, or his disability or death. This filing reflects equity-based compensation rather than an open-market stock purchase or sale.
Vertex Pharmaceuticals executive Ourania Tatsis, EVP and Chief Regulatory & Quality Officer, reported selling 4,500 shares of Vertex common stock on 01/07/2026 at a price of $474.99 per share. After this transaction, she beneficially owned 42,293 shares, all held directly.
The filing notes that the sale was made pursuant to Dr. Tatsis’ company-approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025. Such plans are pre-arranged programs that allow insiders to sell stock according to preset terms, helping them diversify holdings while addressing concerns about trading on material nonpublic information.
Vertex Pharmaceuticals executive Charles F. Jr. Wagner, EVP, CO & FO, reported an option exercise and share sale in company stock. On 01/06/2026 he exercised 9,532 stock options at an exercise price of $189.38 per share, receiving the same number of Vertex common shares. That same day, he sold 9,532 common shares at a price of $461 per share, a transaction coded as a sale. After these transactions, he directly owned 37,725 shares of Vertex common stock. The filing notes that the sale was made under Mr. Wagner’s company-approved Rule 10b5-1 trading plan, which was entered into on 05/09/2025, and that the exercised options were fully vested.
Vertex Pharmaceuticals insider Ourania Tatsis has filed a notice to sell common stock under Rule 144. The filing covers 4,500 shares of Vertex common stock to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $2,137,455.00, against 253,718,831 shares outstanding.
The shares to be sold were acquired mainly through restricted stock vesting on several dates in 2021 and 2024, plus a small purchase through the employee stock purchase plan in May 2024. The notice also reports that Tatsis sold 4,500 Vertex common shares on 12/03/2025 for gross proceeds of $2,024,955.40. By signing, the seller represents not knowing any undisclosed material adverse information about the company’s operations.
Vertex Pharmaceuticals' EVP, CO & FO reported pre-planned stock sales under a Rule 10b5-1 trading plan. On 12/03/2025, the officer sold 7,000 shares of Vertex common stock at $451 per share and another 7,000 shares at $461 per share, both reported as open-market sales. These transactions were made pursuant to a company-approved Rule 10b5-1 trading plan that Mr. Wagner entered into on 5/9/2025. After the reported sales, he beneficially owned 37,725 shares of Vertex common stock directly.
Vertex Pharmaceuticals executive Dr. Ourania Tatsis reported an open market sale of company stock. On 12/03/2025, she sold 4,500 shares of Vertex common stock at a weighted average price of $449.99 per share, with individual sale prices ranging from $449.99 to $450.00. The transaction was coded as an open market sale and was made under a company-approved Rule 10b5-1 trading plan that Dr. Tatsis entered into on 08/21/2025. After this sale, she beneficially owned 46,793 shares of Vertex common stock directly.